1. Scrip
  2. >>R&D
  3. >>Clinical Trials

DBV Technologies Misses With Viaskin Peanut Allergy Patch

 
• By Alexandra Shimmings

The French firm's share price nearly halved on disappointing Phase III data for Viaskin while those of its rival, Aimmune, shot up, but all hope for the patch product is not yet lost.

Peanut Butter Jelly Sandwich_1200
No Jam Today but maybe Jam Tomorrow for Viaskin Peanut • Source: Shutterstock

DBV Technologies SA patch therapy for peanut allergy Viaskin Peanut missed the primary endpoint in its Phase III PETITES study, sending the company's share price down on NASDAQ by 46% to $25.95 on 23 Oct.

While the top-line results showed a significant response with a favorable tolerability profile, with 35.3% of patients responding to Viaskin...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.